Telehealth & Digital Health

The medtech firm reports a 19% revenue surge and a return to profitability, validating its new pure-play strategy focused on the surgical market.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

A groundbreaking surgical technique in Gujarat eliminates neck scars, offering new hope and faster recovery for millions with thyroid conditions.

A new AI-powered technology can spot deadly high potassium levels using a simple smartwatch ECG, a breakthrough that could transform remote patient care.

Seattle nonprofit Ryther launches Juniper, an intensive program for teens, addressing a critical gap in care for older adolescents with mood and anxiety.

Taimei Technology and C&R Research forge a strategic alliance, deploying advanced AI to automate and accelerate drug development in Asia's key research hub.

Diathrive Health and AliveCor's KardiaComplete partner to offer an integrated solution for diabetes and heart disease, combating fragmented care and rising costs.

With a key FDA decision looming, Cristcot hires Rayna Herman to lead the commercial strategy for its first-in-class ulcerative colitis therapy, ngHCA.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

A new FDA-cleared system offers hope against postpartum hemorrhage, the leading cause of maternal death, earning its maker a prestigious Edison Award.

A novel medical food for IBS shows remarkable efficacy in new studies, exceeding FDA benchmarks for pain relief and solving the long-standing issue of taste.

A major investment in natural killer cell immunotherapy aims to revolutionize treatment for Canada's most fatal women's cancer after decades of stagnation.

The new Gibco CTS DynaXS bioreactor aims to unlock scalable production, making life-saving cell therapies more accessible and affordable for patients.

A startup's partnership with industry giant Alcon promises to make vision assessment faster, more precise, and accessible to patients everywhere.

Noema Pharma's investigational drug cendifensine not only cut hot flashes by 92% but also aided weight loss and mood, promising a new non-hormonal era.

A new partnership aims to create a continuous data stream from surgery to recovery, using AI to predict and prevent costly gastrointestinal complications.

Eli Lilly begins a crucial Phase 2 study for a novel, non-addictive pain drug from Confo Therapeutics, a major step in the hunt for an opioid alternative.

A new peer-reviewed study shows Glucotrack's fully implantable glucose monitor is accurate for 240 days, a key step towards a 3-year, no-wearable future.

A new collaboration leverages a vast cord blood bank and advanced AI to create off-the-shelf cell therapies, promising a new era in regenerative medicine.